HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- cyclohexyl- 6- (((2- methoxyethyl)(methyl)amino)methyl)- N- methylthiazolo(3,2- a)benzimidazole- 2- carboxamide

an mGluR1 antagonist; structure in first source

Also Known As:

YM 202074; YM-202074; YM202074

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - N-cyclohexyl-6-(((2-methoxyethyl)(methyl)amino)methyl)-N-methylthiazolo(3,2-a)benzimidazole-2-carboxamide: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzimidazoles: 245
      - N-cyclohexyl-6-(((2-methoxyethyl)(methyl)amino)methyl)-N-methylthiazolo(3,2-a)benzimidazole-2-carboxamide: 1
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiazoles: 392
    - N-cyclohexyl-6-(((2-methoxyethyl)(methyl)amino)methyl)-N-methylthiazolo(3,2-a)benzimidazole-2-carboxamide: 1

Experts

1.	Hayashibe, Satoshi: 1 article (01/2008)
2.	Kawabata, Shigeki: 1 article (01/2008)
3.	Kohara, Atsuyuki: 1 article (01/2008)
4.	Okada, Masamichi: 1 article (01/2008)
5.	Shitaka, Yoshitsugu: 1 article (01/2008)
6.	Takahashi, Masayasu: 1 article (01/2008)
7.	Tamura, Seiji: 1 article (01/2008)
8.	Yatsugi, Shin-Ichi: 1 article (01/2008)

Related Diseases

1.	Stroke (Strokes) 01/29/2008 - "These results suggest that YM-202074 exhibits great potential as a novel neuroprotective agent for the treatment of stroke." 01/29/2008 - "Neuroprotective effects of the selective type 1 metabotropic glutamate receptor antagonist YM-202074 in rat stroke models."
2.	Infarction (Infarctions) 01/29/2008 - "Results clearly demonstrate a dose-dependent improvement of neurological deficit and reduction of the infarct volume in both the hemisphere and cortex when YM-202074 was infused intravenously immediately after occlusion at a dose of 10 or 20 mg/kg/h for 0.5 h followed by a dose of 2.5 or 5 mg/kg/h for 23.5 h, respectively. "

Related Drugs and Biologics

1.	Neuroprotective Agents
2.	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)